Clinical trial
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used…
NCT00224133 · Watson Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00224133 |
|---|---|
| Title | The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months |
| Official title | A Multi-Center, Open-Label Evaluation of the Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia |
| Lead sponsor | Watson Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | Silodosin |
| Enrollment | 661 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 27, 2010 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: